{"id":"09da92eb-e9fb-5b34-9c96-ed7965d7b191","stable_key":"8ccb5461-efe2-5d95-9869-950d7cd50575:tadalafil-half-life","predicate":"sustains","statement":"Tadalafil plasma concentrations declined nearly monoexponentially with a mean half-life of 17.5 hours, with 5th and 95th percentiles of 11.5 and 29.6 hours.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"e33df657-b388-5a21-a1c0-e830a0e50053","mechanism_event_label":"Tadalafil plasma concentrations declined nearly monoexponentially with a mean half-life of 17.5 hours, with 5th and 95th percentiles of 11.5 and 29.6 hours.","subject":{"id":"9820ebfe-515d-50cc-9b44-2bd2be220325","slug":"tadalafil","display_name":"Tadalafil","entity_type_key":"drug"},"object":{"id":"80623479-3813-550d-9740-703838fdde70","slug":"tadalafil-plasma-exposure","display_name":"Plasma tadalafil exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e33df657-b388-5a21-a1c0-e830a0e50053","stable_key":"8ccb5461-efe2-5d95-9869-950d7cd50575:tadalafil-half-life-event","event_type":"observed_relationship","label":"Tadalafil plasma concentrations declined nearly monoexponentially with a mean half-life of 17.5 hours, with 5th and 95th percentiles of 11.5 and 29.6 hours.","description":"Tadalafil plasma concentrations declined nearly monoexponentially with a mean half-life of 17.5 hours, with 5th and 95th percentiles of 11.5 and 29.6 hours.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9820ebfe-515d-50cc-9b44-2bd2be220325","slug":"tadalafil","display_name":"Tadalafil","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"80623479-3813-550d-9740-703838fdde70","slug":"tadalafil-plasma-exposure","display_name":"Plasma tadalafil exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"Single dose and 10 days","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"237 healthy subjects across 13 clinical pharmacology studies, with a separate multiple-dose study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Single 2.5 to 20 mg doses, and 10 or 20 mg once daily for 10 days","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Healthy subjects only. No clinically meaningful effect of body mass index, age, gender or smoking was identified, and food had negligible effect on bioavailability.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"237 healthy subjects across 13 clinical pharmacology studies, with a separate multiple-dose study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Tadalafil plasma concentrations declined nearly monoexponentially with a mean half-life of 17.5 hours, with 5th and 95th percentiles of 11.5 and 29.6 hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Tadalafil pharmacokinetics in healthy subjects. (2006). https://pubmed.ncbi.nlm.nih.gov/16487221/ DOI: 10.1111/j.1365-2125.2005.02553.x","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Plasma tadalafil pharmacokinetics","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a7885b3f-bd0d-5c36-8b20-87deb4adbb7c","evidence_kind":"source_excerpt","locator":"Lines 78-87","start_line":78,"end_line":87,"excerpt":"## tadalafil-half-life\nTadalafil plasma concentrations declined nearly monoexponentially with a mean half-life of 17.5 hours, with 5th and 95th percentiles of 11.5 and 29.6 hours.\nModel/species: 237 healthy subjects across 13 clinical pharmacology studies, with a separate multiple-dose study\nTissue/system: Plasma tadalafil pharmacokinetics\nExposure: Single 2.5 to 20 mg doses, and 10 or 20 mg once daily for 10 days\nRoute: Oral\nDuration: Single dose and 10 days\nLimits: Healthy subjects only. No clinically meaningful effect of body mass index, age, gender or smoking was identified, and food had negligible effect on bioavailability.\nPrimary reference: Tadalafil pharmacokinetics in healthy subjects. (2006). https://pubmed.ncbi.nlm.nih.gov/16487221/ DOI: 10.1111/j.1365-2125.2005.02553.x\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"cca24ae7-e036-525c-a440-4cc2e38ccb4d","stable_key":"import-8ccb5461-efe2-5d95-9869-950d7cd50575","title":"Tadalafil: PDE5 occupancy, the cGMP route and three measured endpoints (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of seven primary studies resolved by PubMed title search, with every abstract read and all DOIs cross-checked against live PubMed metadata. Two references carry an unresolvable erratum and are recorded as corrected. Study-specific doses, effect sizes and limitations retained. Not publisher full text.","file_path":"","sha256":"3df8ec8f7114f983e8cae9fbc54912d3ac5b5f962454afea9dd8d4438c94cded","revision_id":"510acdea-65ae-57a6-b743-68e031ff1f05","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}